Pritumumab

Pritumumab is a human monoclonal antibody against vimentin[1] developed by Nascent Biotech, which is traded under the OTC ticker symbol nbio[2]. It is in clinical trials for the treatment of glioma.[3] The FDA granted orphan drug designation in 2015.

Pritumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
Targetvimentin
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6440H9968N1708O2016S42
Molar mass144923.04 g·mol−1
 NY (what is this?)  (verify)

The target of Pritumumab, cell surface vimentin, has been implicated in the replication of coronavirus, specifically in Severe acute respiratory syndrome coronavirus (SARS-CoV), which raised significant fears during 2002 and 2003.

An article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) researched cell surface vimentin as a potential target in the treatment of conditions related to the Coronavirus.[4]

On June 17th, 2020 Nascent Biotech [5] announced after receiving early In-Vitro study results that Pritumumab, (PTB), will be advanced to laboratory-based animal studies. Nascent founder and Advisory Board Chairman Dr. Mark Glassy commented, "the laboratory results were consistent with our Brain Cancer in vitro studies and this is the next step in investigational development of PTB as potential use with COVID-19 and related Viral Infections." [6]

Nascent Biotech[7]has partnered with Manhattan Biosolutions[8] on the development of an advanced BCG vaccine for COVID-19.

According to Manhattan Bioloutions, "BCG is a live non-pathogenic bacterium that stimulates diverse innate and adaptive immune responses and is well-known for its long safety track record as a tuberculosis vaccine. Based on our preclinical experience with the rBCG candidates for oncology indications, we expect that rBCG against SARS-CoV-2 will be possible to develop. Together, we will be in a strong position to advance the discovery and development of an innovative vaccination platform against coronaviruses.”[9]

References
  1. WHO Drug Information
  2. https://www.marketwatch.com/investing/stock/nbio
  3. Nascent Biologics Proven Cancer Cure Back in the Hands Of U.S. Inventor After 27 Years In Japan
  4. Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7
  8. http://manhattanbiosolutions.com/
  9. http://manhattanbiosolutions.com/2020/05/12/covid-19-vaccine/


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.